🔗 Share this article Individuals Coming Off Weight-Loss Medications Put On Weight at a Quadrupled Rate Than Those on Conventional Diets Obesity treatment often requires long-term strategies. New research indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise plans. Findings released in a major medical journal points out that while overweight individuals often shed substantial amounts of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month after stopping. "Individuals purchasing such medications must be aware of the potential of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb. This pace of regain suggests a return to original weight within about one and a half years. Analyzing Therapies The research, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting. Scientists point out that individuals who shed pounds through diet and exercise usually experience a more gradual creep back—approximately 0.1 kg a month—post-intervention. Explaining the Fast Regain Experts propose the way of the injections is key to understanding the amplified weight return. The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger. "Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert. "Withdrawal of this medication means hunger is uncontrolled, making overeating much more probable." An Ongoing Disease? Health authorities suggest the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications. Professionals contend that, considering the significant potential of relapse, the therapy might need to be life-long. This opinion is supported by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," akin to managing conditions like high blood pressure. User Experiences Users who have discontinued the medication describe a intense return of appetite. "It was like something activating and you're instantly starving," recalled an individual. This challenge is compounded if users have not established sustainable lifestyle or habit changes during treatment. Significant Interest Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high. Adoption is greater among women compared to males. The middle-aged demographic shows the highest usage rates. A large proportion obtain the medications through private prescriptions rather than public health services. Finally, experts stress that while the jabs are potent agents for shedding pounds, they are not a magic cure and long-term success relies on integrated lifestyle management.
Obesity treatment often requires long-term strategies. New research indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise plans. Findings released in a major medical journal points out that while overweight individuals often shed substantial amounts of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month after stopping. "Individuals purchasing such medications must be aware of the potential of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb. This pace of regain suggests a return to original weight within about one and a half years. Analyzing Therapies The research, which looked at dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting. Scientists point out that individuals who shed pounds through diet and exercise usually experience a more gradual creep back—approximately 0.1 kg a month—post-intervention. Explaining the Fast Regain Experts propose the way of the injections is key to understanding the amplified weight return. The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger. "Long-term administration of GLP-1 concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert. "Withdrawal of this medication means hunger is uncontrolled, making overeating much more probable." An Ongoing Disease? Health authorities suggest the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications. Professionals contend that, considering the significant potential of relapse, the therapy might need to be life-long. This opinion is supported by pharmaceutical companies, who state that the results "highlight the long-term nature of obesity," akin to managing conditions like high blood pressure. User Experiences Users who have discontinued the medication describe a intense return of appetite. "It was like something activating and you're instantly starving," recalled an individual. This challenge is compounded if users have not established sustainable lifestyle or habit changes during treatment. Significant Interest Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high. Adoption is greater among women compared to males. The middle-aged demographic shows the highest usage rates. A large proportion obtain the medications through private prescriptions rather than public health services. Finally, experts stress that while the jabs are potent agents for shedding pounds, they are not a magic cure and long-term success relies on integrated lifestyle management.